After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going ...

Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy. | Salspera ...

BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved kidney failure drug ...

After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes ...

Generate Biomedicines IPO highlights AI-driven drug discovery, strong backing, promising pipeline, and investor confidence ...

Biotech IPOs fell to a decade low in 2025 Investors expect more listings amid easing rate pressure Policy clarity under Trump has reduced worst-case fears Late-stage drug pipelines drawing renewed ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As many biotechs face financial ...

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor ...

LB Pharmaceuticals secured a much-needed US$285m late Wednesday from its upsized Nasdaq IPO, the first US biotech new issue since February. The biotech sold 84.3% of shares outstanding, with more than ...

MapLight Therapeutics Inc.’s (NASDAQ: MPLT) initial public offering tempted some huge insider buying. Kinder Morgan Inc. (NYSE: KMI), MSC Industrial Direct Co. Inc. (NYSE: MSM), and others also saw ...

The broadening out of the stock market rally is starting to show up in the initial public offering market, as well, with eight private companies making their Wall Street debuts this week—and only two ...

Despite world-class AI-biotech research, a Nobel Prize-winning protein design lab and proximity to global AI expertise, ...